fingolimod

Fingolimod is an oral small molecule immunomodulator used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. It acts as a sphingosine 1-phosphate receptor modulator by binding to sphingosine 1-phosphate receptors (S1PRs), particularly subtypes 1, 3, 4, and 5. This mechanism prevents lymphocytes from exiting lymph nodes into the peripheral circulation, thereby reducing immune-mediated inflammation in the central nervous system associated with MS. Fingolimod was developed by Novartis and was first approved for use in MS in 2010[5][6][1].

Brand names

GilenyaTascenso ODTGilenia

Other names

fingolimod hydrochloride2-amino-2-(4-octylphenylethyl)propane-1,3-diol2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol